Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable treatment option for patients with metastatic melanoma harbouring BRAF(V600) mutations. We assessed the safety of vemurafenib in a large population of patients with few alternative treatment options; we report updated 2-year safety. Methods: This was an open-label, multicentre study of vemurafenib (960 mg bid) in patients with previously treated or untreated BRAF mutation-positive metastatic melanoma (cobas (R) 4800 BRAF(V600) Mutation Test). The primary end-point was safety; efficacy end-points were secondary. An exploratory analysis was performed to assess safety outcomes in patients with long duration of response (DOR) (>= 12 or >= 24 months)...
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonin...
Background: Approximately 50% of melanomas harbor activating (V600) mutations in the serinethreonine...
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have sh...
Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable tre...
Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable tre...
Background The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable trea...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
TBackground: The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, show...
BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BR...
BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BR...
vemurafenib has improved progres-sion-free survival and overall survival in patients with BRAFV600-m...
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonin...
Background: Approximately 50% of melanomas harbor activating (V600) mutations in the serinethreonine...
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have sh...
Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable tre...
Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable tre...
Background The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable trea...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows ...
TBackground: The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, show...
BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BR...
BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BR...
vemurafenib has improved progres-sion-free survival and overall survival in patients with BRAFV600-m...
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonin...
Background: Approximately 50% of melanomas harbor activating (V600) mutations in the serinethreonine...
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have sh...